Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Affiliation:
      Children's Cancer Therapy Development Institute, Beaverton, OR 97005, USA
      Electrical and Computer Engineering, Texas Tech University, Lubbock, TX 79409, USA
      Division of Hematology-Oncology, University of California, Los Angeles, CA 90095, USA
      The Jackson Laboratory, Bar Harbor, ME 04609, USA
      Department of Pathology & Laboratory Medicine, UC Davis Health System, Sacramento, CA 95817, USA
      Department of Epidemiology and Biostatistics, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA
      School of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
      Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
      Patient-Directed Consultations, San Francisco, CA 94116, USA
      Department of Family Medicine, University of California San Francisco, San Francisco, CA 94143, USA
    • Subject Terms:
    • Subject Terms:
    • Abstract:
      Nonrhabdomyosarcoma soft-tissue sarcomas (STSs) are a class of 50+ cancers arising in muscle and soft tissues of children, adolescents, and adults. Rarity of each subtype often precludes subtype-specific preclinical research, leaving many STS patients with limited treatment options should frontline therapy be insufficient. When clinical options are exhausted, personalized therapy assignment approaches may help direct patient care. Here, we report the results of an adult female STS patient with relapsed undifferentiated pleomorphic sarcoma (UPS) who self-drove exploration of a wide array of personalized Clinical Laboratory Improvement Amendments (CLIAs) level and research-level diagnostics, including state of the art genomic, proteomic, ex vivo live cell chemosensitivity testing, a patient-derived xenograft model, and immunoscoring. Her therapeutic choices were also diverse, including neoadjuvant chemotherapy, radiation therapy, and surgeries. Adjuvant and recurrence strategies included off-label and natural medicines, several immunotherapies, and N-of-1 approaches. Identified treatment options, especially those validated during the in vivo study, were not introduced into the course of clinical treatment but did provide plausible treatment regimens based on FDA-approved clinical agents.
    • Journal Subset:
      Biomedical; Europe; Peer Reviewed; UK & Ireland
    • ISSN:
      1357-714X
    • MEDLINE Info:
      NLM UID: 9709257
    • Publication Date:
      20200604
    • Publication Date:
      20200605
    • DOI:
      http://dx.doi.org/10.1155/2020/6312480
    • Accession Number:
      143523605
  • Citations
    • ABNT:
      BERLOW, N. E. et al. Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma. Sarcoma, [s. l.], p. 1–11, 2020. DOI 10.1155/2020/6312480. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=143523605. Acesso em: 12 ago. 2020.
    • AMA:
      Berlow NE, Grasso CS, Quist MJ, et al. Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma. Sarcoma. June 2020:1-11. doi:10.1155/2020/6312480
    • APA:
      Berlow, N. E., Grasso, C. S., Quist, M. J., Cheng, M., Gandour-Edwards, R., Hernandez, B. S., Michalek, J. E., Ryan, C., Spellman, P., Pal, R., Million, L. S., Renneker, M., & Keller, C. (2020). Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma. Sarcoma, 1–11. https://doi.org/10.1155/2020/6312480
    • Chicago/Turabian: Author-Date:
      Berlow, Noah E., Catherine S. Grasso, Michael J. Quist, Mingshan Cheng, Regina Gandour-Edwards, Brian S. Hernandez, Joel E. Michalek, et al. 2020. “Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma.” Sarcoma, June, 1–11. doi:10.1155/2020/6312480.
    • Harvard:
      Berlow, N. E. et al. (2020) ‘Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma’, Sarcoma, pp. 1–11. doi: 10.1155/2020/6312480.
    • Harvard: Australian:
      Berlow, NE, Grasso, CS, Quist, MJ, Cheng, M, Gandour-Edwards, R, Hernandez, BS, Michalek, JE, Ryan, C, Spellman, P, Pal, R, Million, LS, Renneker, M & Keller, C 2020, ‘Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma’, Sarcoma, pp. 1–11, viewed 12 August 2020, .
    • MLA:
      Berlow, Noah E., et al. “Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma.” Sarcoma, June 2020, pp. 1–11. EBSCOhost, doi:10.1155/2020/6312480.
    • Chicago/Turabian: Humanities:
      Berlow, Noah E., Catherine S. Grasso, Michael J. Quist, Mingshan Cheng, Regina Gandour-Edwards, Brian S. Hernandez, Joel E. Michalek, et al. “Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma.” Sarcoma, June 2020, 1–11. doi:10.1155/2020/6312480.
    • Vancouver/ICMJE:
      Berlow NE, Grasso CS, Quist MJ, Cheng M, Gandour-Edwards R, Hernandez BS, et al. Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma. Sarcoma [Internet]. 2020 Jun [cited 2020 Aug 12];1–11. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=143523605